|
1
|
Huang AY, Golumbek P, Ahmadzadeh M, Jaffee
E, Pardoll D and Levitsky H: Role of bone marrow-derived cells in
presenting MHC class I-restricted tumor antigens. Science.
264:961–965. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Restifo NP, Esquivel F, Kawakami Y,
Yewdell JW, Mulé JJ, Rosenberg SA and Bennink JR: Identification of
human cancers deficient in antigen processing. J Exp Med.
177:265–272. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li L, Liu D, Hutt-Fletcher L, Morgan A,
Masucci MG and Levitsky V: Epstein-Barr virus inhibits the
development of dendritic cells by promoting apoptosis of their
monocyte precursors in the presence of granulocyte
macrophage-colony-stimulating factor and interleukin-4. Blood.
99:3725–3734. 2000. View Article : Google Scholar
|
|
4
|
Lambrecht BN, Salomon B, Klatzmann D and
Pauwels RA: Dendritic cells are required for the development of
chronic eosinophilic airway inflammation in response to inhaled
antigen in sensitized mice. J Immunol. 160:4090–4097.
1998.PubMed/NCBI
|
|
5
|
Banchereau J and Steinman RM: Dendritic
cells and the control of immunity. Nature. 392:245–252. 1998.
View Article : Google Scholar
|
|
6
|
Steinman RM, Pack M and Inaba K: Dendritic
cells in the T-cell areas of lymphoid organs. Immunol Rev.
156:25–37. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan MC, Mommaas AM, Drijfhout JW, Jordens
R, Onderwater JJ, Verwoerd D, Mulder AA, van der Heiden AN,
Scheidegger D, Oomen LC, Ottenhoff TH, Tulp A, Neefjes JJ and
Koning F: Mannose receptor mediated uptake of antigens strongly
enhances HLA class II-restricted antigen presentation by cultured
dendritic cells. Eur J Immunol. 27:2426–2435. 1997. View Article : Google Scholar
|
|
8
|
Nair SK, Hull S, Coleman D, Gilboa E,
Lyerly HK and Morse MA: Induction of carcinoembryonic antigen
(CEA)-specific cytotoxic T-lymphocyte responses in vitro using
autologous dendritic cells loaded with CEA peptide or CEA RNA in
patients with metastatic malignancies expressing CEA. Int J Cancer.
82:121–124. 1999. View Article : Google Scholar
|
|
9
|
Timmerman JM and Levy R: Dendritic cell
vaccines for cancer immunotherapy. Annu Rev Med. 50:507–529. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lodge PA, Jones LA, Bader RA, Murphy GP
and Salgaller ML: Dendritic cell-based immunotherapy of prostate
cancer: immune monitoring of a phase II clinical trial. Cancer Res.
60:829–833. 2000.PubMed/NCBI
|
|
11
|
Nestle FO, Alijagic S, Gilliet M, Sun Y,
Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of
melanoma patients with peptide or tumor lysate-pulsed dendritic
cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bell D, Young JW and Banchereau J:
Dendritic cells. Adv Immunol. 72:255–324. 1999. View Article : Google Scholar
|
|
13
|
Henderson RA, Nimgaonkar MT, Watkins SC,
Robbins PD, Ball ED and Finn OJ: Human dendritic cells genetically
engineered to express high levels of the human epithelial tumor
antigen mucin (MUC-1). Cancer Res. 56:3763–3770. 1996.PubMed/NCBI
|
|
14
|
Ribas A, Bui LA, Butterfield LH, Vollmer
CM, Jilani SM, Dissette VB, Glaspy JA, McBride WH and Economou JS:
Antitumor protection using murine dendritic cells pulsed with
acid-eluted peptides from in vivo grown tumors of different
immunogenicities. Anticancer Res. 19:1165–1170. 1999.
|
|
15
|
Miller PW, Sharma S, Stolina M,
Butterfield LH, Luo J, Lin Y, Dohadwala M, Batra RK, Wu L, Economou
JS and Dubinett SM: Intratumoral administration of adenoviral
interleukin 7 gene-modified dendritic cells augments specific
antitumor immunity and achieves tumor eradication. Hum Gene Ther.
11:53–65. 2000. View Article : Google Scholar
|
|
16
|
Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q,
Yu Y, Hamada H and Wang J: Lymphotactin gene-modified bone marrow
dendritic cells act as more potent adjuvants for peptide delivery
to induce specific antitumor immunity. J Immunol. 161:6238–6244.
1998.PubMed/NCBI
|
|
17
|
Celluzzi CM and Falo LD Jr: Physical
interaction between dendritic cells and tumor cells results in an
immunogen that induces protective and therapeutic tumor rejection.
J Immunol. 160:3081–3085. 1998.
|
|
18
|
Ribas A, Butterfield LH, McBride WH,
Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY,
Glaspy JA and Economou JS: Genetic immunization for the melanoma
antigen MART-1/Melan-A using recombinant adenovirus-transfected
murine dendritic cells. Cancer Res. 57:2865–2869. 1997.
|
|
19
|
Lyakh LA, Koski GK, Young HA, Spence SE,
Cohen PA and Rice NR: Adenovirus type 5 vector induces dendritic
cell differentiation in human CD14+ monocytes cultured
under serum-free conditions. Blood. 99:600–608. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lundqvist A, Choudhury A, Nagata T,
Andersson T, Quinn G, Fong T, Maitland N, Pettersson S, Paulie S
and Pisa P: Recombinant adenovirus vector activates and protects
human monocyte derived dendritic cells from apoptosis. Hum Gene
Ther. 13:1541–1549. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miller G, Lahrs S, Pillarisetty VG, Shah
AB and DeMatteo RP: Adenovirus infection enhances dendritic cell
immunostimulatory properties and induces natural killer and
T-cell-mediated tumor protection. Cancer Res. 62:5260–5266.
2002.
|
|
22
|
Kirk CJ, Hartigan-O’Connor D and Mulé JJ:
The dynamics of the T cell antitumor response: chemokine-secreting
dendritic cells can prime tumor-reactive T cells extranodally.
Cancer Res. 61:8794–8802. 2001.PubMed/NCBI
|
|
23
|
Kirk CJ, Hartigan-O’Connor D, Nickoloff
BJ, Chamberlain JS, Giedlin M, Aukerman L and Mule JJ: T
cell-dependent antitumor immunity mediated by secondary lymphoid
tissue chemokine: augmentation of dendritic cell-based
immunotherapy. Cancer Res. 61:2062–2070. 2001.PubMed/NCBI
|
|
24
|
Baggiolini M, Dewald B and Moser B: Human
chemokines: an update. Annu Rev Immunol. 15:675–705. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gunn MD, Tangemann K, Tam C, Cyster JG,
Rosen SD and Williams LT: A chemokine expressed in lymphoid high
endothelial venules promotes the adhesion and chemotaxis of naïve T
lymphocytes. Proc Natl Acad Sci USA. 95:258–263. 1998.PubMed/NCBI
|
|
26
|
Cyster JG: Chemokines and the homing of
dendritic cells to the T cell areas of lymphoid organs. J Exp Med.
189:447–450. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chan VW, Kothakota S, Rohan MC,
Panganiban-Lustan L, Gardner JP, Wachowicz MS, Winter JA and
Williams LT: Secondary lymphoid-tissue chemokine (SLC) is
chemotactic for mature dendritic cells. Blood. 93:3610–3616.
1999.PubMed/NCBI
|
|
28
|
Hromas R, Kim CH, Klemsz M, Krathwohl M,
Fife K, Cooper S, Schnizlein-Bick C and Broxmeyer HE: Isolation and
characterization of Exodus-2, a novel CC chemokine with a unique 37
amino acid carboxyl-terminal extension. J Immunol. 159:2554–2558.
1997.PubMed/NCBI
|
|
29
|
Willimann K, Legler DF, Loetscher M, Roos
RS, Delgado MB, Clark-Lewis I, Baggiolini M and Moser B: The
chemokine SLC is expressed in T cell areas of lymph nodes and
mucosal lymphoid tissues and attracts activated T cells via CCR7.
Eur J Immunol. 28:2025–2034. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nagira M, Imai T, Hieshima K, Kusuda J,
Ridanpää M, Takagi S, Nishimura M, Kakizaki M, Nomiyama H and
Yoshie O: Molecular cloning of a novel human CC chemokine secondary
lymphoid-tissue chemokine that is a potent chemoattractant for
lymphocytes and mapped to chromosome 9p13. J Biol Chem.
272:19518–19524. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gunn MD, Kyuwa S, Tam C, Kakiuchi T,
Matsuzawa A, Williams LT and Nakano H: Mice lacking expression of
secondary lymphoid organ chemokine have defects in lymphocyte
homing and dendritic cell localization. J Exp Med. 189:451–460.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soto H, Wang W, Strieter RM, Copeland NG,
Gilbert DJ, Jenkins NA, Hedrick J and Zlotnik A: The CC chemokine
SLC binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA.
95:8205–8210. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sharma S, Stolina M, Luo J, Strieter RM,
Burdick M, Zhu LX, Batra RK and Dubinett SM: Secondary lymphoid
tissue chemokine mediates T cell-dependent antitumor responses in
vivo. J Immunol. 164:4558–4563. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sharma S, Stolina M, Zhu L, Lin Y, Batra
R, Huang M, Strieter R and Dubinett SM: Secondary lymphoid organ
chemokine reduces pulmonary tumor burden in spontaneous murine
bronchoalveolar cell carcinoma. Cancer Res. 61:6406–6412.
2001.PubMed/NCBI
|
|
35
|
Nishimura N, Nishioka Y, Shinohara T,
Ogawa H, Yamamoto S, Tani K and Sone S: Novel centrifugal method
for simple and highly efficient adenovirus-mediated green
fluorescence protein gene transfection into human monocyte-derived
dendritic cells. J Immunol Methods. 253:113–124. 2001. View Article : Google Scholar
|
|
36
|
Nishimura N, Nishioka Y, Shinohara T and
Sone S: Enhanced efficiency by centrifugal manipulation of
adenovirus-mediated interleukin 12 gene transduction into human
monocyte-derived dendritic cells. Hum Gene Ther. 12:333–346. 2001.
View Article : Google Scholar
|
|
37
|
Arthur JF, Butterfield LH, Roth MD, Bui
LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH and
Economou JS: A comparison of gene transfer methods in human
dendritic cells. Cancer Gene Ther. 4:17–25. 1997.PubMed/NCBI
|
|
38
|
Zhong L, Granelli-Piperno A, Choi Y and
Steinman RM: Recombinant adenovirus is an efficient and
non-perturbing genetic vector for human dendritic cells. Eur J
Immunol. 29:964–972. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fasbender A, Zabner J, Chillón M, Moninger
TO, Puga AP, Davidson BL and Welsh MJ: Complexes of adenovirus with
polycationic polymers and cationic lipids increase the efficiency
of gene transfer in vitro and in vivo. J Biol Chem. 272:6479–6489.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dietz AB and Vuk-Pavlović S: High
efficiency adenovirus-mediated gene transfer to human dendritic
cells. Blood. 91:392–398. 1998.PubMed/NCBI
|
|
41
|
Christopherson KW II, Campbell JJ and
Hromas RA: Transgenic overexpression of the CC chemokine CCL21
disrupts T-cell migration. Blood. 98:3562–3568. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Förster R, Schubel A, Breitfeld D, Kremmer
E, Renner-Müller I, Wolf E and Lipp M: CCR7 coordinates the primary
immune response by establishing functional microenvironments in
secondary lymphoid organs. Cell. 99:23–33. 1999.PubMed/NCBI
|
|
43
|
Bromley SK, Thomas SY and Luster AD:
Chemokine receptor CCR7 guides T cell exit from peripheral tissues
and entry into afferent lymphatics. Nat Immunol. 6:895–901. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bacon KB, Premack BA, Gardner P and Schall
TJ: Activation of dual T cell signaling pathways by the chemokine
RANTES. Science. 269:1727–1730. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dairaghi DJ, Soo KS, Oldham ER, Premack
BA, Kitamura T, Bacon KB and Schall TJ: RANTES-induced T cell
activation correlates with CD3 expression. J Immunol. 160:426–433.
1998.PubMed/NCBI
|
|
46
|
Appay V, Dunbar PR, Cerundolo V, McMichael
A, Czaplewski L and Rowland-Jones S: RANTES activates
antigen-specific cytotoxic T lymphocytes in a mitogen-like manner
through cell surface aggregation. Int Immunol. 12:1173–1182. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guo Z, Zhang M, Tang H and Cao X: Fas
signal links innate and adaptive immunity by promoting
dendritic-cell secretion of CC and CXC chemokines. Blood.
106:2033–2041. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Flanagan K, Moroziewicz D, Kwak H, Hörig H
and Kaufman HL: The lymphoid chemokine CCL21 costimulates naive T
cell expansion and Th1 polarization of non-regulatory
CD4+ T cells. Cell Immunol. 231:75–84. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Marsland BJ, Bättig P, Bauer M, Ruedl C,
Lässing U, Beerli RR, Dietmeier K, Ivanova L, Pfister T, Vogt L,
Nakano H, Nembrini C, Saudan P, Kopf M and Bachmann MF: CCL19 and
CCL21 induce a potent proinflammatory differentiation program in
licensed dendritic cells. Immunity. 22:493–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
